Gene Silencing Market – By Type, By Application, By End Use – Global Forecast 2025 - 2034

Gene Silencing Market Size

The global gene silencing market was valued at USD 9.6 billion in 2024. The market is expected to reach from USD 10.6 billion in 2025 to USD 28.5 billion in 2034, growing at a CAGR of 11.6% during the forecast period. Gene silencing is a process used to turn off or "silence" specific genes in a cell. This helps to stop certain genes from producing proteins that might cause diseases or health issues.
 

The growth of the global gene silencing market is mainly stimulated by the rising prevalence of genetic disorders, which has significantly expanded the demand for advanced therapeutic solutions. Genetic disorders, such as cystic fibrosis, Duchenne Muscular Dystrophy (DMD), Sickle Cell Anemia, and different inherited cancers, are getting more predominant around the world, contributing to the need for innovative therapeutics such as therapeutics developed with gene silencing process. For instance, in the U.S., approximately 1,000 new cases of cystic fibrosis (CF) are diagnosed each year.
 

In the European Union, the condition affects about 1 in every 2,000 to 3,000 newborns, highlighting the broad prevalence of genetic disorders. Thus, the growing prevalence of genetic disorders is stimulating the strong demand for effective treatment options. Gene silencing technologies are emerging as a promising solution to combat these conditions by preventing faulty genes from causing health issues.
 

Additionally, more people are becoming aware of genetic conditions, and with the help of new advancements in biotechnology, there has been great progress in developing these treatments. RNA interference (RNAi) and antisense oligonucleotides (ASOs) are two key technologies that offer potential medications for a wide range of hereditary diseases. These advancements are not only giving hope for people affected by these conditions but are also accelerating the expansion of the market.
 

Moreover, the patients and healthcare providers are exploring more precise and effective treatment alternatives which is developing the demand for targeted treatments, altogether stimulating the growth of the market. Targeted treatments are designed to specifically target the underlying causes of diseases at the genetic level, offering a more personalized approach to treatment. A report from PubMed in 2023 highlights the development of targeted therapies that has revolutionized cancer treatment, offering improved efficacy with reduced side effects compared to traditional treatments such as chemotherapy.
 

This move toward targeted treatments is accelerating the advancement and adoption of gene silencing technologies, such as RNA interference (RNAi) and antisense oligonucleotides (ASOs), which can particularly silence or modify faulty genes responsible for genetic disorders. Thus, the demand for more effective, personalized medications is expanding, hence the market is anticipated to grow in the forward direction, fueled by advancements in biotechnology and developing patient awareness.
 

Gene Silencing Market Trends

• Developments in gene silencing methods have improved the specificity and efficacy of medications. These advancements in methodologies enable the precise targeting of disease-causing genes, progressing therapeutic outcomes. A study from PubMed reports that for diseases where the issue is connected to abnormal gene expression, RNAi can be an effective tool.
   
• Moreover, the significant investments from both public and private sectors are fueling research and development in gene silencing technology. For instance, recently the National Institute of Neurological Disorder and Stroke established the Ultra-rare Gene-based Treatment (URGenT) Network, which is centered on accelerating the improvement of quality treatments for ultra-rare neurological diseases, providing funding and resources to advance these medications into clinical applications.
   
• These investments are crucial in driving the next generation of quality treatments, illustrating the commitment of both government and private sectors to this innovative field.
   
• Therefore, as the number of individuals requiring these treatments continues to rise, the demand, investment, and research for advanced treatments such as gene silencing, will simultaneously increase, thereby accelerating the market growth.
   

Trump Administration Tariffs

• Tariffs on Chinese imports, including essential components such as oligonucleotides, lipid nanoparticles (LNPs), reagents, delivery vectors, and laboratory automation modules, many of which are vital for gene silencing platforms, are expected to raise production costs across the global market.
   
• A significant number of manufacturers and research organizations currently rely on China for cost-effective sourcing of these critical materials and tools. With the implementation of tariffs, supply chains could experience significant strain, leading to increased manufacturing costs and potential delays in research and development timelines.
   
• Therefore, companies operating in the gene silencing market are expected to reevaluate their sourcing strategies to minimize dependency on Chinese suppliers. This is likely to accelerate a transition toward alternative manufacturing and sourcing hubs such as India, South Korea, Ireland, and Eastern European nations, where geopolitical risks are lower and operational efficiency is comparatively favorable.
   
• However, in the short term, this strategic realignment may present several challenges, including delays in clinical and preclinical project pipelines, increased costs associated with validating new vendors, and temporary disruptions in the supply and integration of critical subsystems such as siRNA/miRNA delivery systems, nucleic acid synthesis tools, and bioinformatics support infrastructure.
   

Gene Silencing Market Analysis

Based on type, the market is segmented into product and services. The product segment is further bifurcated into RNAi, CRISPR-Cas9, antisense oligonucleotides (ASOs), and other products. The market was estimated at USD 9.6 billion in 2024. The product segment held revenue of USD 7.7 billion in 2024, and the segment is poised for significant growth at a CAGR of 11.6% during the forecast period.
 

• The growth of the segment is highly attributed to the increasing adoption of advanced technologies such as RNA interference (RNAi), CRISPR-Cas9, and antisense oligonucleotides (ASOs). These innovations are enabling highly targeted treatments at the genetic level, revolutionizing healthcare approaches and offering more effective solutions for a wide range of diseases.
   
• RNA interference (RNAi) is proving to be a transformative tool, since it can turn off genes that lead to diseases such as cancer, viral infections, and different hereditary conditions. Meanwhile, CRISPR-Cas9 provide researchers with an incredibly precise tool to alter genes, offering treatment options for inherited disorders that were once considered untreatable.
   
• Antisense oligonucleotides (ASOs) are also making a significant impact, particularly in the treatment of genetic conditions such as Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), by regulating gene expression.
   
• For instance, according to a report from the U.S. Center for Disease Control (CDC) in 2025, Duchenne muscular dystrophy (DMD) affects approximately 1 in every 5,000 males aged 5 to 9 years.
   
• Therefore, as the prevalence of these genetic disorders is increasing, so does the demand for innovative technologies such as gene silencing for the development of advance therapeutics to combat the conditions, thereby fostering the segment’s growth in the fast-paced market of gene silencing.

Based on the application, the gene silencing market is segmented into drug discovery and development, therapeutic manufacturing, agricultural application, and other applications. The drug and discovery segment is further bifurcated neurology, oncology, infectious diseases, genetic disorders, and other drug discoveries and developments. The drug discovery and development segment dominated the market with a market share of 51.8% in 2024.
 

• RNA interference (RNAi), CRISPR-Cas9, and antisense oligonucleotides (ASOs) are examples of gene silencing technologies that are becoming increasingly significant in drug development. These developments are crucial for figuring out the root cause of diseases.
   
• The gene-based drug discovery has benefited enormously from the use of RNAi technology. For conditions such as cancer, Duchenne muscular dystrophy, and other genetic illnesses, these developments have been especially useful.
   
• For instance, a 2023 study published by the National Center for Biotechnology Information notes that RNAi therapy applies the body's natural RNA interference mechanisms to achieve gene regulation in clinical settings.
   
• The U.S. Food and Drug Administration (FDA) has approved four RNA therapeutics, a market estimated to reach USD 31.1 billion by 2032. These RNAi therapeutics include patisiran (Onpattro, 2018), givosiran (Givlaari, 2019), lumasiran (Oxlumo, 2020), and inclisiran (Leqvio, 2021). Each small interfering RNA (siRNA) drug targets a specific mRNA transcript to address a particular disease. Several additional siRNA candidates such as fitusiran, nedosiran, teprasiran, tivanisiran, and vutrisiran have reached phase III clinical trials, while many more RNAi-based therapies are progressing through early-stage clinical trials or preclinical development.
   
• Thus, as the research and clinical trial for the development and discover of various gene therapeutics increase, so does the demand for the gene silencing tools in the sector of drug discovery and development, thereby stimulating the growth of the segment.
   

Based on the end use, market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, CROs and CMOs, and other end users. The pharmaceutical and biotechnology companies segment held revenue of USD 4.4 billion in 2024, and the segment is poised for significant growth at a CAGR of 11.8% during the forecast period.
 

• The growth of the pharmaceutical and biotechnology companies segment in the gene silencing market is mostly stimulated by the increasing demand for advanced technologies to support drug discovery and development. Companies are actively expanding their R&D pipelines, leveraging gene silencing to address unmet medical needs.
   
• Moreover, the segment is experiencing significant growth due to the rising number of collaborations between biotech firms and pharmaceutical companies, as well as the growing need for precision medicine.
   
• For example, in 2025, a collaboration between City Therapeutics and Bausch + Lomb highlights the increasing role of gene silencing in developing new treatments. The two companies have joined forces to create an RNAi-based treatment for geographic atrophy, a condition that leads to vision loss, further exhibiting gene silencing technologies' demand to treat complex health conditions.
   
• Therefore, as more partnerships form to accelerate the development of targeted therapies, gene silencing technologies are becoming an essential tool for addressing a range of diseases.

In 2024, North America accounted for the largest share of 42.5% in the global gene silencing market and the U.S. is forecasted to reach USD 11.1 billion by 2034.
 

• The U.S. holds significant market share within the North American market, stimulated by ongoing technological advancements and an increasing emphasis on patient-focused healthcare options.
   
• Moreover, the leading companies and research institutes of the U.S. play a vital role in the development of advanced gene silencing treatments such as RNAi, among others.
   
• Additionally, backing from regulatory authorities and the increasing investments in healthcare technology are contributing to the growth and development of the market in the country.
   

Europe: The gene silencing market in the UK is projected to grow significantly from 2025 to 2034.
 

• The UK has a strong biopharmaceutical industry which invests broadly in research and development of innovative targeted therapies and tools, such as gene silencing.
   
• For instance, according to data from Statista, pharmaceutical R&D expenditure reached around USD 10.2 billion (EUR 9 billion) in 2022. Thus, this significant investment strengthens the UK's position in developing advanced treatments such as gene silencing treatments.
   
• Thus, this in turn will fuel the demand and enhance the visibility and precision of the complex treatments.
   

Asia Pacific: The gene silencing market in the Japan is projected to grow significantly from 2025 to 2034.
 

• Japan has a significant elderly population, resulting in an increased need for age-related treatments, including treatments for chronic diseases such as cancer, neurodegenerative diseases, among others, impelling the demand for targeted therapies and technologies such as gene silencing, stimulating the growth for the market.
   
• For example, in 2023 projections from the World Economic Forum revealed that 1 in 10 people in Japan are aged 80 years and above which was about one-third of the population.
   
• Additionally, as healthcare standards continue to rise in the country, the need for innovative tools and technologies will further propel the market for gene silencing in the country.
   

In Middle East and Africa region, Saudi Arabia is projected to grow significantly from 2025 to 2034.
 

• The growth of the gene silencing market is highly influenced by the increasing investment in healthcare infrastructure, including advanced gene therapies, such as RNAi, ASOs, among others, which is propelling the growth of the market in the country.
   
• For instance, Saudi Arabia's Vision 2030 includes significant investments in healthcare infrastructure, which are aimed at enhancing the quality and accessibility of medical services including gene silencing treatments across the country to treat inherited genetic diseases.
   
• Moreover, the Multidisciplinary Digital Publishing Institute (MDPI) in 2023 reported that the prevalence of genetic disorders in Saudi Arabia is higher compared to many other countries due to the high rate of consanguinity (marriage between blood relatives).
   
• This has heightened the demand for targeted gene silencing therapies to manage and treat inherited genetic disorders such as thalassemia, sickle cell anemia, and Duchenne muscular dystrophy.
   

Gene Silencing Market Share

The market for gene silencing is competitive, with both established players and new entrants consistently innovating and developing advanced products. In terms of revenue, the market is primarily dominated by the top 5 players, which include Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Danaher, and Agilent Technologies, which together account for approximately 40% of the total market share. These companies are focusing on the development of advanced technologies enabling market players to strengthen their position in this growing sector.
 

Gene Silencing Market Companies

Some of the eminent market participants operating in the gene silencing industry include:

• Agilent Technologies
• Bio-Rad Laboratories
• Cellecta
• Danaher
• GenScript
• Merck KGaA
• New England Biolabs
• Qiagen
• Revvity Discovery
• Santa Cruz Botechnology
• Thermo Fisher Scientific
   
• Bio-Rad Laboratories is a well-established player known for its leading solutions. The company has an extensive portfolio of various applications. The company is heavily investing in research and development to facilitate advancement in technologies. For instance, in 2024 the company has invested 295.9 million in research and development as per the company's annual report.
   
• Agilent Technologies has a robust geographical presence which enables it to enhance its market reach. Agilent Technologies operates in more than 110 countries thus comprising of a strong distribution network.
   

Gene Silencing Industry News:

• In July 2024, Agilent Technologies Inc. announced a definitive agreement to acquire BIOVECTRA, a prominent contract development and manufacturing organization (CDMO) specializing in biologics, highly potent active pharmaceutical ingredients, and targeted therapeutic molecules. This acquisition strengthens Agilent's expertise in CDMO services, particularly in three core areas: oligonucleotides, CRISPR-based therapeutics, and other advanced biomanufacturing capabilities.
   
• In May 2024, Merck announced a definitive agreement to acquire Mirus Bio, a life science company specializing in the development and commercialization of transfection reagents. Mirus Bio's products, including TransIT-VirusGEN, facilitate the delivery of genetic material into cells and are essential in the production of viral vectors used for cell and gene therapies. This strategic acquisition supports Merck's efforts to accelerate growth in next-generation technologies. As a key player in viral vector production, Merck aims to expand global access to the transformative potential of cell and gene therapies for patients worldwide.
   

The gene silencing market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Product
  • RNAi
    • miRNA
    • siRNA
    • Other RNAi products
  • CRISPR-Cas9
    • CRISPR kits and reagents
    • CRISPR libraries
    • Other CRISPR-CAS 9 products
  • Antisense oligonucleotides (ASOs)
  • Other products
• Services

Market, By Application

• Drug discovery and development      
  • Neurology
  • Oncology
  • Infectious diseases
  • Genetic disorders
  • Other drug discoveries and developments
• Therapeutics manufacturing
• Agricultural applications
• Other applications

Market, By End Use

• Pharmaceutical and biotechnology companies
• Academic and research institutes
• CROs and CMOs
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE